Cannabinoid content and the price of medical cannabis in Canada vary with licensed producer, location of production, and production method. We track cannabinoid content and pricing data for all available dried cannabis flowers and milled blends to understand how these prices change over time, and to highlight offerings with the best value.
The data for this summary was taken March 30th 2017. Publicly available information on producer websites and newsletters was logged for all available dried cannabis flower and blends in the ACMPR. Actual cannabinoid content and non-compassionate price were logged for each listing and, in the cases where ranges of cannabinoids were given, midpoint averages were used. For the producers offering volume discounts, we’ve used the cost for the smallest size available. We do not show sales tax, shipping, or pricing incentives for ordering an entire month’s prescription in one order. In cases where the same variety was offered by two different providers, and for varieties that were available in whole flower and blended form, data was logged for each instance.
All flower and blended dried cannabis offerings were categorized according to cannabinoid content. Offerings with ratios of 1.4+ THC:CBD were considered THC offerings. Those with 1.4-0.3 THC:CBD were considered 1:1 offerings, while the remainder (<0.3 THC:CBD) were considered CBD offerings.
There were 155 dried cannabis blends and flowers available from the 22 Licensed Producers providing cannabis to ACMPR patients. The average number of selections per producer is just over 7—a slight decrease from earlier this month. Most producers (21 of 22) carried at least 5 THC offerings and at least one offering containing some amount of CBD. Varieties containing negligible amounts of THC (compared to CBD) were available from 7 of 22 providers (up from 6 last in early March).
We want to note that we’ve omitted Hydropothecary’s line of fully decarboxylated dried cannabis designed for oral ingestion from previous studies. They are now included in this study. Although the product is designed to be taken as an edible, it is still categorized as dried cannabis. These products are unique in the market currently and, we’ll start to compare them against other fully decarboxylated dried product as they become available.
Of the 155 available offerings, 122 of them (79%) contained significant amounts of THC to CBD. Seven of the 155 (4.5%) were found to have significant amounts of CBD with negligible amounts of THC. The remaining 17% were found to be 1:1 offerings with comparable cannabinoid content (26 offerings).
The average price per gram for a gram of cannabis in the ACMPR was found to be $9.12.
Prices are typically higher for CBD chemotypes: the average price of 100mg of CBD was $7.39 for the second half of March. Average prices per producer remained the same as earlier this month, and ranged from $5.92 to $10.00 per 100 milligrams of CBD.
For 100mg of THC/CBD from a 1:1 chemotype, the average price is $5.36. Producer averages ranged from $3.88 to $9.95 per 100 milligrams of either cannabinoid. The maximum end of the range is down from earlier this month where we saw listings for 1:1 chemotypes just above $11.00 per 100 milligrams.
We’ve started to track average cannabinoid content for THC and CBD chemotypes. Please note, increasing cannabinoid content does not necessarily equate to increased efficacy.
This summary tracks dried cannabis listings from around the ACMPR. Much of the data presented here is shown as summarized producer averages comprised of several offerings. For specific information on each cannabis variety, as well as information on each producer, check out Lift and read the reviews in the review section.
Featured image via Wikipedia.